Frederique Penault-Llorca

Summary

Affiliation: Centre Jean Perrin
Country: France

Publications

  1. ncbi request reprint [Diagnostic approach for breast cancer classification]
    Frederique Penault-Llorca
    Département de pathologie et de biopathologie, Centre Jean Perrin, 63011 Clermont Ferrand Cedex, France
    Rev Prat 63:1384-90. 2013
  2. pmc SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases
    Jocelyne Jacquemier
    Institut Paoli Calmettes, Biopathology Department, 232 Bd Ste Marguerite, 13009, Marseille, France
    BMC Cancer 13:351. 2013
  3. doi request reprint [Update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France]
    Frederique Penault-Llorca
    Centre Jean Perrin, Departement de Pathologie, 58, rue Montalembert, 63011 Clermont Ferrand, France
    Ann Pathol 30:357-73. 2010
  4. ncbi request reprint [EGFR expression in colorectal cancer and role in tumorigenesis]
    Frederique Penault-Llorca
    Centre Jean Perrin, 58 rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex
    Bull Cancer 92:S5-11. 2005
  5. ncbi request reprint [The pathologist and EGFR in 2004: I like you, nor do it]
    Frederique Penault-Llorca
    Centre Jean Perrin, 58 rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex
    Ann Pathol 24:416-26. 2004
  6. doi request reprint [HER2 and gastric cancer. Recommendations for clinical practice in 2011]
    Frederique Penault-Llorca
    Departement de Pathologie, Centre Jean Perrin, BP 392, 58, rue Montalembert, 63011 Clermont Ferrand Cedex, France EA 4233, Universite d Auvergne, 63000 Clermont Ferrand Cedex, France
    Ann Pathol 31:78-87. 2011
  7. ncbi request reprint Is there an immunohistochemical technique definitively valid in epidermal growth factor receptor assessment?
    Frederique Penault-Llorca
    Centre Jean Perrin, Departement de Pathologie, 63011 Clermont Ferrand Cedex, France
    Oncol Rep 16:1173-9. 2006
  8. ncbi request reprint [Roles of the pathologist in neoadjuvant chemotherapy: evaluation of response, prognostic and predictive factors]
    Frederique Penault-Llorca
    Departement de Pathologie, Centre Jean Perrin, 58 rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex 1
    Ann Pathol 23:555-63. 2003
  9. ncbi request reprint [Comments on the new American Joint Committee on Cancer TNM staging for breast cancer. What's new for the pathologist?]
    Frederique Penault-Llorca
    Departement de Pathologie, Centre Jean Perrin, 58 rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex 1
    Ann Pathol 23:492-5. 2003
  10. ncbi request reprint [Prognostic value of epidermal growth factor receptor]
    Frederique Penault-Llorca
    Departement de Pathologie, Centre Jean Perrin, 58, rue Montalembert, BP 392, 63011 Clermont Ferrand
    Bull Cancer 90:S192-6. 2003

Detail Information

Publications51

  1. ncbi request reprint [Diagnostic approach for breast cancer classification]
    Frederique Penault-Llorca
    Département de pathologie et de biopathologie, Centre Jean Perrin, 63011 Clermont Ferrand Cedex, France
    Rev Prat 63:1384-90. 2013
    ....
  2. pmc SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases
    Jocelyne Jacquemier
    Institut Paoli Calmettes, Biopathology Department, 232 Bd Ste Marguerite, 13009, Marseille, France
    BMC Cancer 13:351. 2013
    ....
  3. doi request reprint [Update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France]
    Frederique Penault-Llorca
    Centre Jean Perrin, Departement de Pathologie, 58, rue Montalembert, 63011 Clermont Ferrand, France
    Ann Pathol 30:357-73. 2010
    ..Once acquired, this knowledge must be perpetuated by the observation of rules of good technical practice (internal and external controls, quality assurance programs)...
  4. ncbi request reprint [EGFR expression in colorectal cancer and role in tumorigenesis]
    Frederique Penault-Llorca
    Centre Jean Perrin, 58 rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex
    Bull Cancer 92:S5-11. 2005
    ..EGFR testing may be required before targeted treatment. An exciting endpoint might be the functional and dynamic evaluation of EGFR and downstream proteins for patients, before and during treatment...
  5. ncbi request reprint [The pathologist and EGFR in 2004: I like you, nor do it]
    Frederique Penault-Llorca
    Centre Jean Perrin, 58 rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex
    Ann Pathol 24:416-26. 2004
    ..An exciting endpoint might be the functional and dynamic evaluation of EGFR and downstream proteins, for patients, before and during treatment. The exact role of the pathologist still have to be accurately determined...
  6. doi request reprint [HER2 and gastric cancer. Recommendations for clinical practice in 2011]
    Frederique Penault-Llorca
    Departement de Pathologie, Centre Jean Perrin, BP 392, 58, rue Montalembert, 63011 Clermont Ferrand Cedex, France EA 4233, Universite d Auvergne, 63000 Clermont Ferrand Cedex, France
    Ann Pathol 31:78-87. 2011
    ..This will ensure accurate and consistent HER2 testing results, which will allow the appropriate selection of patients eligible for treatment with trastuzumab...
  7. ncbi request reprint Is there an immunohistochemical technique definitively valid in epidermal growth factor receptor assessment?
    Frederique Penault-Llorca
    Centre Jean Perrin, Departement de Pathologie, 63011 Clermont Ferrand Cedex, France
    Oncol Rep 16:1173-9. 2006
    ..No scoring system showed, to date, its accuracy, and more studies have to be conducted with an evaluation of the response to cetuximab, possibly with a correlation with FISH amplification in colorectal carcinoma...
  8. ncbi request reprint [Roles of the pathologist in neoadjuvant chemotherapy: evaluation of response, prognostic and predictive factors]
    Frederique Penault-Llorca
    Departement de Pathologie, Centre Jean Perrin, 58 rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex 1
    Ann Pathol 23:555-63. 2003
    ..The evaluation of the post treatment tumor residue helps in determinating tumor response to treatment, establishing prognosis and adjusting adjuvant regimens. Standard histopathological procedures are mandatory...
  9. ncbi request reprint [Comments on the new American Joint Committee on Cancer TNM staging for breast cancer. What's new for the pathologist?]
    Frederique Penault-Llorca
    Departement de Pathologie, Centre Jean Perrin, 58 rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex 1
    Ann Pathol 23:492-5. 2003
    ..These new parameters should help in the collection of uniform informations and in a more accurate management of breast cancer patients...
  10. ncbi request reprint [Prognostic value of epidermal growth factor receptor]
    Frederique Penault-Llorca
    Departement de Pathologie, Centre Jean Perrin, 58, rue Montalembert, BP 392, 63011 Clermont Ferrand
    Bull Cancer 90:S192-6. 2003
    ..Because of its role in oncogenesis and its prognostic value, REGF might in the future become a therapeutic target...
  11. ncbi request reprint [Epidermal growth factor receptors: status evaluation methods and tumor expression]
    Frederique Penault-Llorca
    Centre Jean Perrin, 58, rue Montalembert, BP 392, 63011 Clermont Ferrand
    Bull Cancer 90:S186-91. 2003
    ..EGFR testing may be required before targeted treatment. An exciting endpoint would be the functional and dynamic evaluation of EGFR and downstream proteins for patients, before and during treatment...
  12. ncbi request reprint [Micrometastatic disease and residual axillary disease. Breast cancer as an example Alct]
    F Penault-Llorca
    Departement de Pathologie, Centre Jean Perrin, 58, rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex 01, France
    Cancer Radiother 10:338-42. 2006
    ..We have to learn how to evaluate accurately those new parameters to treat the best way our patients...
  13. doi request reprint [Node negative breast cancer. Beyond international consensus: a pragmatic approach]
    Frederique Penault-Llorca
    Centre Jean Perrin, Service de Pathologie, 58, rue Montalembert BP 392, 63011 Clermont Ferrand, France
    Bull Cancer 98:807-25. 2011
    ....
  14. ncbi request reprint [Targeted therapies: the question of target detection and evaluation]
    Frederique Penault-Llorca
    Centre Jean Perrin, BP392, 63011 Clermont Ferrand Cedex
    Bull Cancer 94:F245-8. 2007
    ....
  15. ncbi request reprint [Assessment of HER2 status in breast cancer]
    Frederique Penault-Llorca
    Departement de Pathologie, Centre Jean Perrin, 58, rue Montalembert, BP 392, 63011 Clermont Ferrand
    Bull Cancer 91:S211-5. 2004
    ..The importance of adhesion to quality assurance programs is underlined. Finally, the different national testing guidelines are discussed...
  16. ncbi request reprint Achieving higher pathological complete response rates in HER-2-positive patients with induction chemotherapy without trastuzumab in operable breast cancer
    Frederique Penault-Llorca
    Centre Jean Perrin, Clermont Ferrand, France
    Oncologist 12:390-6. 2007
    ..Finally, there was a tendency toward a higher DFS rate for HER-2-positive patients who achieved a pCR compared with HER-2-positive patients who did not...
  17. ncbi request reprint Prognostic value of residual node involvement in operable breast cancer after induction chemotherapy
    Hervé Curé
    Centre Jean Perrin, Clermont Ferrand, France
    Breast Cancer Res Treat 76:37-45. 2002
    ....
  18. ncbi request reprint Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy
    Sophie Amat
    Centre Jean Perrin, Bureau de Recherche Clinique, B P 392, 63011 Clermont Ferrand Cedex 1, France
    Int J Oncol 20:791-6. 2002
    ..The association between evolution of the histological grade following chemotherapy and response to treatment may prove valuable for clinicians as they make their decision regarding patient therapy...
  19. ncbi request reprint Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome
    Frederique Penault-Llorca
    Department of Pathology, Centre Jean Perrin, BP 392, 63011 Clermont Ferrand Cedex, France
    Int J Oncol 22:1319-25. 2003
    ..P53 and Ki67 significantly increased after treatment (p<0.005 and p<0.0005). SBR grade, proliferation markers, ER evaluated before and after treatment predicted disease-free survival (DFS) in univariate analysis...
  20. ncbi request reprint Sequential addition of an anthracycline-based regimen to docetaxel as neoadjuvant chemotherapy in patients with operable breast cancer
    Sophie Amat
    Centre Jean Perrin, Clermont Ferrand, France
    Clin Breast Cancer 7:262-9. 2006
    ..The objective of this phase II study was to attempt to maximize response and survival in patients with bulky, operable breast cancer by combining sequential neoadjuvant docetaxel to a semi-intensive anthracycline-based regimen...
  21. ncbi request reprint Single static view 99mTc-sestamibi scintimammography predicts response to neoadjuvant chemotherapy and is related to MDR expression
    Anne Cayre
    Department of Pathology, Centre Jean Perrin, Clermont Ferrand, France
    Int J Oncol 20:1049-55. 2002
    ..05) in invasive ductal carcinoma. A pre-treatment single-view 99mTc-sestamibi scintimammography is an excellent predictor of MDR1 chemoresistance and was highly specific of a lack of pathological response to chemotherapy...
  22. ncbi request reprint Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy
    Olivier Tacca
    Bureau de Recherche Clinique, Centre Jean Perrin 58, rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex 1, France
    Oncologist 12:636-43. 2007
    ..In this work, NCT induced variations in HR status in 23% of patients. A positive switch in HR status after NCT could be an indicator of better prognosis for patient outcome...
  23. ncbi request reprint High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer
    Sophie Amat
    Centre Jean Perrin, 58 rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex 1, France
    Breast Cancer Res Treat 94:255-63. 2005
    ..It is concluded that, outside any other 'biological' factor, residual disease in breast and nodes must be strongly considered after an induction chemotherapy so as to choose adjuvant treatment for the individual patient...
  24. doi request reprint [Ovarian epithelial dysplasia: Description of a dysplasia scoring scheme]
    Gautier Chene
    Departement de Chirurgie, Centre Jean Perrin, Clermont Ferrand, France
    Ann Pathol 31:3-10. 2011
    ..The objective of this study was to describe histopathological features of ovarian dysplasia and to propose a dysplasia scoring sheme with a cut-off...
  25. ncbi request reprint Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer
    Catherine Abrial
    Centre Jean Perrin, Bureau de Recherche Clinique, 58 rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex 1, France
    Oncologist 10:242-9. 2005
    ..There was no case of severe cardiac toxicity, thrombocytopenia, or any other serious adverse events. In conclusion, whereas this regimen was relatively well tolerated, it appears inferior to other regimens and its use is not recommended...
  26. doi request reprint Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer
    Frederique Penault-Llorca
    Centre Jean Perrin, 63011 Clermont Ferrand, France
    Hum Pathol 39:1221-8. 2008
    ..Finally, evidence of pCR in nodes was associated with a better prognosis. pCR should be defined as an absence of node invasion, and in the breast, either absence of tumor or tumor residue less than 5% of the tumor...
  27. ncbi request reprint [An aggressive subtype of breast carcinoma]
    Marie Melanie Dauplat
    Departement de Pathologie, Centre Jean Perrin, 58 rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex 1
    Ann Pathol 23:611-2. 2003
  28. ncbi request reprint [Sentinel lymph node biopsy for breast cancer after neoadjuvant chemotherapy: influence of nodal status before treatment]
    Guillaume Le Bouedec
    Service Chirurgie, Centre de Lutte Contre le Cancer d Auvergne Jean Perrin, 58, rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex 1
    Bull Cancer 93:415-9. 2006
    ..To determine feasibility and accuracy of SLN biopsy in locally advanced breast cancer treated by neoadjuvant chemotherapy...
  29. doi request reprint Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy
    Frederique Penault-Llorca
    Centre Jean Perrin, Bureau de Recherche Clinique, Clermont Ferrand Cedex 1, France
    Oncologist 13:1235-45. 2008
    ..Because these factors were correlated, no multivariate model was done. The main clinical fact is that there were significant correlations between clinical and pathological responses and variations in the biological factors studied...
  30. ncbi request reprint [Place of anatomopathology in evaluation of response to neoadjuvant chemotherapy. Prognostic and predictive markers: example of breast cancer]
    Catherine Abrial
    Unite de recherche clinique, Centre Jean Perrin, 58, rue Montalembert, BP392, 63011 Clermont Ferrand Cedex 1
    Bull Cancer 93:663-8. 2006
    ..The evaluation of the post-treatment tumour residue helps to determine tumour response to treatment and prognosis, as well as to adjust adjuvant regimens. It is essential to standardize these histopathological procedures...
  31. pmc Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification
    Anne Cayre
    Departement de Pathologie, Centre Jean Perrin, 58 rue Montalembert, BP392, 63011 Clermont Ferrand Cedex, France
    Breast Cancer Res 9:R64. 2007
    ..The interpretation pitfalls, optimal threshold values, assay duration and complexity of each kit were also considered...
  32. ncbi request reprint Randomized Phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer
    Aurélie Cabrespine
    Centre Jean Perrin, Clermont Ferrand, France
    Urology 67:354-9. 2006
    ..Paclitaxel and carboplatin has demonstrated antitumor activity in HRPC. The therapeutic benefit of such treatment was compared with that of mitoxantrone...
  33. pmc Is There a Relationship between Ovarian Epithelial Dysplasia and Infertility?
    Gautier Chene
    Department of Histopathology, Centre Jean Perrin, Clermont Ferrand 63000, France
    Obstet Gynecol Int 2012:429085. 2012
    ..53 in ovulation induction group and 5.1 in infertile group). Conclusion. These results raise questions as to the responsibility of drugs used to induce ovulation and/or infertility itself in the genesis of ovarian epithelial dysplasia...
  34. doi request reprint [The Fallopian tube odyssey: from the ovary to the tube. About high-grade serous ovarian carcinoma]
    Gautier Chene
    Centre Jean Perrin, Departement d Anatomie et de Cytologie Pathologiques, 58 rue Montalembert, 63000 Clermont Ferrand, France
    Bull Cancer 100:757-64. 2013
    ..In light of recent and past molecular studies, we will review and discuss these two theories...
  35. ncbi request reprint O(6)-methylguanine-DNA methyl transferase gene expression and prognosis in breast carcinoma
    Anne Cayre
    Department of Pathology, Centre Jean Perrin, BP 392, 63011 Clermont Ferrand Cedex, France
    Int J Oncol 21:1125-31. 2002
    ..This difference is also significant using the COX model (p<0.05). In breast cancer, tumor MGMT expression was not predictive of response to CPM. A low MGMT expression was significantly related to poor survival...
  36. doi request reprint Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions
    Gautier Chene
    Department of Histopathology, Centre Jean Perrin, ERTICA Research Team, Clermont Ferrand, France
    Clin Cancer Res 19:2873-82. 2013
    ..We investigated the level of telomere shortening and genomic instability in early and preinvasive stages of ovarian cancer, serous tubal intraepithelial carcinoma (STIC), and tubo-ovarian dysplasia (TOD)...
  37. doi request reprint Emerging technologies for assessing HER2 amplification
    Frederique Penault-Llorca
    Department de Pathologie, Centre Jean Perrin, 63011 Clermont Ferrand Cedex, France
    Am J Clin Pathol 132:539-48. 2009
    ..Moreover, signals do not decay over time. This review discusses recent publications regarding CISH and SISH testing, including results scoring and concordance between FISH and immunohistochemical analysis...
  38. ncbi request reprint [Immunochemistry evaluation of HER2 status in infiltration breast cancer: technical protocol and interpretation guidelines]
    Frederique Penault-Llorca
    Service d Anatomie et Cytologie Pathologiques, Centre Jean Perrin, 58 Rue de Montalembert, 63001 Clermont Ferrand, France
    Ann Pathol 22:150-7. 2002
    ..FISH should be used for complementary assessment of 2+ cases (on condition that they have not been fixed in Bouin's liquid) and for the calibration of the IHC technique...
  39. pmc Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer
    Abderrahim El Guerrab
    Department of Oncogenetic, Centre Jean Perrin, Clermont Ferrand, France
    PLoS ONE 6:e25080. 2011
    ....
  40. pmc aHIF but not HIF-1alpha transcript is a poor prognostic marker in human breast cancer
    Anne Cayre
    Department of Pathology and INSERM U484, Centre Jean Perrin, Clermont Ferrand, France
    Breast Cancer Res 5:R223-30. 2003
    ..A natural antisense transcript (aHIF) complementary to the 3'-untranslated region of HIF-1alpha mRNA was described recently...
  41. ncbi request reprint Does 99mTc-sestamibi uptake discriminate breast tumors?
    Anne Cayre
    Department of Pathology, Centre Jean Perrin, Clermont Ferrand, France
    Cancer Invest 22:498-504. 2004
    ..005). This difference is also significant using the Cox model (p < 0.05). Uptake of 99mTc-sestamibi (low vs. high) discriminates breast tumors with different histopathological characteristics and prognosis...
  42. ncbi request reprint [An inflammatory tumor-like lesion of the breast]
    Florence Mishellany
    Departement de Pathologie, Centre Jean Perrin, 58 rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex 1
    Ann Pathol 23:613-4. 2003
  43. ncbi request reprint [Classification of preinvasive breast and carcinoma in situ: doubts, controversies, and proposal for new categorizations]
    Marie Melanie Dauplat
    Departement de Pathologie, Centre Jean Perrin, 58, rue Montalembert, BP 392, 63011 Clermont Ferrand
    Bull Cancer 91:S205-10. 2004
    ..The different systems of classifications of those different entities, the most recent molecular biology datas, controversies and consensus are described in this manuscript...
  44. doi request reprint Metastatic breast cancer: overall survival related to successive chemotherapies. What do we gain after the third line?
    Olivier Tacca
    Bureau de Recherche Clinique, Centre Jean Perrin, Clermont Ferrand Cedex 1, France
    Cancer Invest 27:81-5. 2009
    ..In our study, it appeared useful to give several CT lines when possible. Subsequent lines of CT could have a beneficial effect on the survival for some patients with MBC...
  45. doi request reprint Capillary permeability and extracellular volume fraction in uterine cervical cancer as patient outcome predictors: measurements by using dynamic MRI spin-lattice relaxometry
    Véronique Dedieu
    Medical Physics, Department of Centre J Perrin, Clermont Ferrand, France
    J Magn Reson Imaging 27:846-53. 2008
    ..To improve the outcome prediction of uterine cervical carcinoma by measuring the vascular permeability (k(ep)) and the extracellular volume fraction (v(e)) of the tumor from Dynamic T(1)- IRM Relaxometry...
  46. doi request reprint Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer
    Frederique Penault-Llorca
    Department of Pathology, Centre Jean Perrin, EA 4233, Université d Allvergne Clermont 1, Clermont Ferrand 63000, France
    J Clin Oncol 27:2809-15. 2009
    ..89; 95% CI, 0.47 to 1.66; P = .71). CONCLUSION Ki67 expression identifies a subset of patients with ER-positive breast cancer who could be sensitive to docetaxel treatment in the adjuvant setting...
  47. doi request reprint Ovarian epithelial dysplasia and prophylactic oophorectomy for genetic risk
    Gautier Chene
    Department of Surgery, Centre Jean Perrin, rue Montalembert, Clermont Ferrand, France
    Int J Gynecol Cancer 19:65-72. 2009
    ..To make an accurate histopathological description of ovarian dysplasia in a population at genetic risk of ovarian cancer and devise an ovarian dysplasia score...
  48. doi request reprint Experts' opinion: Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status
    Frederique Penault-Llorca
    Centre Jean Perrin, 58 rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex, France
    Breast 22:200-2. 2013
    ....
  49. ncbi request reprint [New entities in pathological classification and new therapeutic options in renal cell carcinoma]
    Jacques Olivier Bay
    Departement d Oncologie Medicale, Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont Ferrand
    Bull Cancer 93:91-100. 2006
    ..Finally, we will present targeted therapy (antiangiogenic drugs and tyrosine kinase inhibitors) with the mechanisms of action, efficacy and appropriate use in the treatment of metastatic renal cell carcinoma...
  50. doi request reprint In vivo efficacy of melanoma internal radionuclide therapy with a 131I-labelled melanin-targeting heteroarylcarboxamide molecule
    Francoise Degoul
    Imagerie moléculaire et thérapie vectorisée, Universite d Auvergne, Clermont Universite, Clermont Ferrand, France
    Int J Cancer 133:1042-53. 2013
    ..Our findings raise [131I]ICF01012 a good candidate for disseminated melanoma treatment and strongly support transfer of [131I]ICF01012 to clinical trial...
  51. doi request reprint Vincristine-induced neuropathy in the rat is not modified by drug-drug interactions with the P-glycoprotein inhibitor verapamil
    David Balayssac
    Laboratoire de Toxicologie, Faculte de Pharmacie, Clermont Universite, Universite d Auvergne, Clermont Ferrand, France
    Chemotherapy 54:336-42. 2008
    ..P-glycoprotein is essential for the functional integrity of blood-tissue barriers, and P-glycoprotein inhibition due to possible drug interactions could lead to adverse neurotoxic reactions...